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Mycobacterium lentiflavum is a recently described
nontuberculous mycobacterium that has mainly clinical
importance in young children with cervical lymphadenitis
and in immunocompromised patients. We describe a case
of chronic pulmonary infection in an immunocompetent
patient. Our observation confirms clinical, diagnostic, and
treatment difficulties in the management of M. lentiflavum
infection.
M
ycobacterium lentiflavum was described as a nontu-
berculous mycobacterium in 1966 (1,2). Most of the
isolates represented fortuitous isolations, although recent-
ly its identification has posed concerns about its possible
clinical importance. M. lentiflavum was mainly isolated
from lymph nodes of young children, while isolations from
other sites (lung specimens included) were described only
in immunocompromised patients (3–9). 
We describe, for the first time, a chronic pulmonary M.
lentiflavum infection in an elderly immunocompetent
woman. Our report confirms the emergence of this nontu-
berculous mycobacteria infection in immunocompetent
patients and underlines the clinical, diagnostic, and thera-
peutic difficulties in its management. 
The Study
In February 2000, dyspnea, productive cough, hemopt-
ysis, weight loss, weakness, and slight fever developed in
a 67-year-old woman with a previous diagnosis of pul-
monary tuberculosis (47 years earlier). A chest radiograph
showed post-tuberculous fibrodystrophy of the right upper
lobe. Ziehl-Neelsen smear gave positive results, and a non-
tuberculous mycobacterium was isolated. Drug-suscepti-
bility tests, performed on agar medium by proportion
method, showed sensitivity to rifampin, ethambutol, and
pyrazinamide and resistance to streptomycin and isoniazid.
Treatment with isoniazid, pyrazinamide, ethambutol, and
rifampin was begun for 3 months without any microbio-
logic changes. The persistence of acid-fast bacilli and non-
tuberculous  Mycobacterium–positive cultures in the
sputum were interpreted as a chronic nontuberculous
mycobacterial colonization not associated with true patho-
genic damage, and no further treatment was undertaken. 
In March 2002, the patient was admitted to our hospital
because of productive cough, weakness, dyspnea, hemop-
tysis, fever, and weight loss. Radiograph and computed
tomography scan showed worsening chest abnormalities,
with the appearance of a widespread reticulonodular alter-
ation and an opacity in the left middle lobe (Figure A). 
The sputum smear was still positive for acid-fast bacil-
li (polymerase chain reaction [PCR] specific for M. tuber-
culosis and  M. avium DNA was negative), and routine
cultures for mycobacteria yielded unidentified scotochro-
mogenic mycobacterium. HIV test was performed to
investigate a possible cause of immune impairment, but it
was negative. Lymphocyte subsets by flow cytometry were
studied and showed normal values. In addition, a killing
test to evaluate macrophage activity was performed, and a
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Figure. A) Pulmonary computed tomographic scan representation
of Mycobacterium lentiflavum lesions. Radiologic image shows the
appearance of a widespread reticulonodular alteration and an
opacity in the left middle lobe. B) Chest radiograph results before
and after 3 months of treatment shows a sustained improvement
of the visible alterations to the left pulmonary middle lobe.diagnosis of chronic granulomatosis disease was excluded.
Concomitantly, cultures from sputum and from bron-
cholavage were performed for either standard bacteria or
fungi (including Pneumocystis carinii). These cultures did
not identify other pathogens. Serologic tests to detect
Chlamydia pneumoniae,  Mycoplasma pneumoniae, and
Legionella species (including urinary antigens) were per-
formed and produced negative results, thus confirming the
pathogenic role of the Mycobacterium lentiflavum.
Susceptibility tests, using proportion methods, showed
sensitivity to clarithromycin, ethambutol, isoniazid, strep-
tomycin, rifabutin, cycloserine, and terizidon and resist-
ance to rifampin, amikacin, kanamycin, pyrazinamide, and
ofloxacin. According to the clinical history, microbiologic
results, and susceptibility pattern (clarithromycin MIC
2 µg/mL), treatment with clarithromycin was initiated. The
patient was released after 10 days with no fever; a slight,
yet progressive, improvement of radiologic features; and a
substantial recovery of the clinical conditions. 
All conventional identification procedures, including
cultural, biochemical, and enzymatic tests, failed to prop-
erly identify the species. Moreover, many questions
remained unresolved, and further clarification was needed
about the origin and effect of treatment on the clinical
response. Because of the need to reach a definitive diagno-
sis, we sent the unidentified Mycobacterium culture to one
of the Italian reference laboratories for mycobacteria.
Two months after hospitalization, the diagnosis of M.
lentiflavum was obtained by analyzing cell wall mycolic
acids by using high-performance liquid chromatographic
test and by nucleic acid sequence analysis of PCR-ampli-
fied 16S ribosomal RNA gene fragments. After 3 months
of clarithromycin treatment, the patient completely recov-
ered, and chest radiograph showed sustained improvement
(Figure B). Mycobacterial investigations, which had pro-
duced negative sputum samples after 1 month of treatment,
once again gave positive results. After a new evaluation of
drug susceptibility that showed no change in drug-resist-
ance pattern, a further treatment with clarithromycin,
ethambutol, rifabutin, and ciprofloxacin was undertaken,
but it was prematurely ended because of poor patient com-
pliance.
At present, after a 3-year follow up, the patient com-
plains of intermittent hemoptysis, weakness, and dyspnea.
Radiographic examinations still show the known wide-
spread reticulonodular alterations, and sputum cultures are
persistently positive for acid-fast bacilli. 
Conclusions
M. lentiflavum is a recently described nontuberculous
mycobacterium (1,2). Most isolates have represented for-
tuitous isolations that required critical evaluation about
their clinical importance. Indeed, as summarized in the
Table,  M. lentiflavum identification has been shown to
cause disease in only few cases. All of these cases were
described in Europe. Most reports describe isolates from
cervical lymphadenitis of very young children (3–9); other
anatomic sites are less frequently implicated (1,7,8). The
few  M. lentiflavum pulmonary cases were described in
immunocompromised patients only (5,8,9). 
We describe, for the first time, a chronic pulmonary
infection due to M. lentiflavum in an immunocompetent
patient. Our observation provides further evidence that this
species should be added to the growing list of nontubercu-
lous mycobacteria, which can cause pulmonary disease in
both immunocompromised and immunocompetent
patients.
Traditional identification techniques are widely insuffi-
cient in providing a correct diagnosis, and more sophisti-
cated diagnostic methods need to be improved.
Susceptibility tests have reliability problems.
When the difficulties in reaching a diagnosis are con-
sidered, the identification standard techniques, based on
the rate of growth, pigmentation, and biochemical tests,
even if well established and relatively inexpensive, are
unable to identify most nontuberculous mycobacteria.
Laboratory methods that perform better, such as high-per-
formance liquid chromatography and genetic investiga-
tions of the 16S rRNA gene fragments, through the use of
nucleic acid probes, sequencing, and amplification, have to
be added to diagnostic protocols for nontuberculous
mycobacteria diagnosis. Moreover, new reference centers
should be created and organized. Cooperation programs
among research laboratories, which have provided a struc-
tured experience with complex methods, have to be imple-
mented, and an effective collaboration should be created. 
In addition to the diagnostic uncertainty, interpreting
the sensitivity tests is also of concern. Information provid-
ed by tests performed on solid medium was discordant and
created serious misunderstanding in the therapeutic choic-
es. Thus, in the presence of nontuberculous mycobacteria,
the susceptibility profile must be performed on liquid
media, and tests on agar by proportion method should be
avoided because of the risk of obtaining false-resistant
results. Because of the difficulties in executing these meth-
ods and interpreting their results, we recommend that the
tests be performed by experienced laboratories that can
maintain feedback for both peripheral laboratories and cli-
nicians. 
In 1998, the Italian National Institute of Health
launched, in accordance with the World Health
Organization and International Union Against
Tuberculosis and Lung Disease, a project to implement
proficiency testing; results from the first (1998–1999) and
second surveys (2000) showed substantial improvement in
the accuracy of drug-susceptibility testing in the network.
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a focused monitoring program were effective in improving
the quality of drug susceptibility results (10).
By describing a recurrent chronic pulmonary infection,
our report provides further evidence of the possible role of
M. lentiflavum as an emerging human pathogen. Our data
also stress the diagnostic and therapeutic difficulties in the
management of this nontuberculous Mycobacterium
infection.
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